November 17, 2022
Via: PharmaphorumThe Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted yesterday by nine to four that the benefits of Xphozah (tenapanor) outweigh its risks when given as a monotherapy to treat high phosphate levels in the blood in adults with CDK […]
July 11, 2024
July 11, 2024
July 19, 2024